Literature DB >> 29307595

Hyperglycemia induced early growth response-1 regulates vascular dysfunction in human retinal endothelial cells.

Gayathree Karthikkeyan1, Ragavachetty Nagaraj Nareshkumar1, Seeneevasan Aberami2, Konerirajapuram Natarajan Sulochana2, Srinivasan Vedantham3, Karunakaran Coral4.   

Abstract

Early growth response-1 (Egr-1) protein upregulation is reported in diabetes and vascular disorders. This study aims at deciphering its role in hyperglycemia induced changes of retinal endothelium. Human retinal endothelial cells (hRECs) were exposed to hyperglycemia (25mM) and normoglycemia (5.5mM). Gene silencing was done using siRNA against Egr-1. Transcript and protein level analysis of Egr-1 and gene targets were done using qPCR and immunoblotting respectively in hRECs, diabetic and nondiabetic human retina and immunofluorescence for localization in retinal sections. Hyperglycemia induced Egr-1 and vascular endothelial growth factor-A (VEGF-A) but not pigment epithelium derived factor (PEDF) in hRECs. Expression of Egr-1 repressor NGFI-A binding protein-2 (NAB-2) was unaltered. Egr-1 downstream gene targets, tissue factor (TF) and intercellular adhesion molecule-1 (ICAM-1) expression were increased in hRECs which was reduced by Egr-1 silencing in hyperglycemia. Diabetic retina, showed an increase in Egr-1, VEGF-A and gene target TF, ICAM-1 but not NAB-2 and PEDF similar to the changes seen in hyperglycemic hRECs. Hyperglycemic induction of Egr-1 and absence of NAB-2 repression in retinal endothelium, up-regulates downstream genes involved in pro-thrombotic and pro-inflammatory pathways linking Egr-1 in diabetes mediated vascular aberration of retina.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Early growth response-1; Endothelial cells; Hyperglycemia; Retina

Mesh:

Substances:

Year:  2018        PMID: 29307595     DOI: 10.1016/j.mvr.2018.01.002

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  7 in total

1.  Hyperglycaemia cause vascular inflammation through advanced glycation end products/early growth response-1 axis in gestational diabetes mellitus.

Authors:  Barathi Rajaraman; Nirupama Ramadas; Sundar Krishnasamy; Vidya Ravi; Atima Pathak; C S Devasena; Krishnan Swaminathan; Arunkumar Ganeshprasad; Ashok Ayyappa Kuppuswamy; Srinivasan Vedantham
Journal:  Mol Cell Biochem       Date:  2019-02-14       Impact factor: 3.396

2.  Egr1 mediates retinal vascular dysfunction in diabetes mellitus via promoting p53 transcription.

Authors:  Haocheng Ao; Bingqian Liu; Haichun Li; Lin Lu
Journal:  J Cell Mol Med       Date:  2019-03-19       Impact factor: 5.310

3.  Chemerin promotes microangiopathy in diabetic retinopathy via activation of ChemR23 in rat primary microvascular endothelial cells.

Authors:  Li Jun; Song Lin-Lin; Song Hui
Journal:  Mol Vis       Date:  2021-09-05       Impact factor: 2.367

4.  Mitochondrial DNA drives noncanonical inflammation activation via cGAS-STING signaling pathway in retinal microvascular endothelial cells.

Authors:  Yue Guo; Ruiping Gu; Dekang Gan; Fangyuan Hu; Gang Li; Gezhi Xu
Journal:  Cell Commun Signal       Date:  2020-10-28       Impact factor: 5.712

5.  Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.

Authors:  Patrick L Mulcrone; Shanique K E Edwards; Daniela N Petrusca; Laura S Haneline; Jesús Delgado-Calle; G David Roodman
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

6.  Metabolism and Health Effects of Rare Sugars in a CACO-2/HepG2 Coculture Model.

Authors:  Amar van Laar; Charlotte Grootaert; Filip Van Nieuwerburgh; Dieter Deforce; Tom Desmet; Koen Beerens; John Van Camp
Journal:  Nutrients       Date:  2022-01-30       Impact factor: 5.717

7.  Downregulation of circ-UBAP2 ameliorates oxidative stress and dysfunctions of human retinal microvascular endothelial cells (hRMECs) via miR-589-5p/EGR1 axis.

Authors:  Yu Jiewei; Zhou Jingjing; Xue Jingjing; Zhang Guilan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.